152 related articles for article (PubMed ID: 38277755)
21. β-Catenin is reduced in membranes of human prolactinoma cells and it is inhibited by temozolomide in prolactin secreting tumor models.
Demarchi G; Valla S; Perrone S; Chimento A; Bonadeo N; Vitale DL; Spinelli FM; Cervio A; Sevlever G; Alaniz L; Berner S; Cristina C
Tumour Biol; 2022; 44(1):85-105. PubMed ID: 35811548
[TBL] [Abstract][Full Text] [Related]
22. Low levels of PRB3 mRNA are associated with dopamine-agonist resistance and tumor recurrence in prolactinomas.
Wang F; Gao H; Li C; Bai J; Lu R; Cao L; Wu Y; Hong L; Wu Y; Lan X; Zhang Y
J Neurooncol; 2014 Jan; 116(1):83-8. PubMed ID: 24135847
[TBL] [Abstract][Full Text] [Related]
23. Phenotype and resistance patterns of 10 resistant prolactinomas.
Araujo-Castro M; Abad López A; Aller Pardo J; Kanaan Kanaan L; Palacios García N
Endocrinol Diabetes Nutr (Engl Ed); 2020 Mar; 67(3):194-204. PubMed ID: 31201099
[TBL] [Abstract][Full Text] [Related]
24. Dopamine agonist-resistant prolactinomas.
Oh MC; Aghi MK
J Neurosurg; 2011 May; 114(5):1369-79. PubMed ID: 21214334
[TBL] [Abstract][Full Text] [Related]
25. The KBTBD6/7-DRD2 axis regulates pituitary adenoma sensitivity to dopamine agonist treatment.
Liu YT; Liu F; Cao L; Xue L; Gu WT; Zheng YZ; Tang H; Wang Y; Yao H; Zhang Y; Xie WQ; Ren BH; Xiao ZH; Nie YJ; Hu R; Wu ZB
Acta Neuropathol; 2020 Sep; 140(3):377-396. PubMed ID: 32572597
[TBL] [Abstract][Full Text] [Related]
26. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy.
Soule SG; Farhi J; Conway GS; Jacobs HS; Powell M
Clin Endocrinol (Oxf); 1996 Jun; 44(6):711-6. PubMed ID: 8759184
[TBL] [Abstract][Full Text] [Related]
27. Characteristics of dynamic magnetic resonance image enhancement in prolactinomas resistant to dopamine agonist therapy.
Guo Q; Erickson BJ; Chang AY; Erickson D
J Investig Med; 2015 Mar; 63(3):529-33. PubMed ID: 25551412
[TBL] [Abstract][Full Text] [Related]
28. Alteration of G alpha subunits mRNA levels in bromocriptine resistant prolactinomas.
Caccavelli L; Morange-Ramos I; Kordon C; Jaquet P; Enjalbert A
J Neuroendocrinol; 1996 Oct; 8(10):737-46. PubMed ID: 8910802
[TBL] [Abstract][Full Text] [Related]
29. Expression of Stem Cell Markers and Dopamine D2 Receptors in Human and Rat Prolactinomas.
Gao Z; Cai L; Lu J; Wang C; Li Q; Chen J; Song X; Chen X; Zhang L; Zheng W; Su Z
Med Sci Monit; 2017 Apr; 23():1827-1833. PubMed ID: 28411401
[TBL] [Abstract][Full Text] [Related]
30. Role of TGF-β1/Smad3-mediated fibrosis in drug resistance mechanism of prolactinoma.
Hu B; Mao Z; Jiang X; He D; Wang Z; Wang X; Zhu Y; Wang H
Brain Res; 2018 Nov; 1698():204-212. PubMed ID: 30055965
[TBL] [Abstract][Full Text] [Related]
31. Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms.
Pivonello C; Patalano R; Negri M; Pirchio R; Colao A; Pivonello R; Auriemma RS
Front Endocrinol (Lausanne); 2021; 12():791633. PubMed ID: 35095761
[TBL] [Abstract][Full Text] [Related]
32. Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists.
Neff LM; Weil M; Cole A; Hedges TR; Shucart W; Lawrence D; Zhu JJ; Tischler AS; Lechan RM
Pituitary; 2007; 10(1):81-6. PubMed ID: 17285366
[TBL] [Abstract][Full Text] [Related]
33. DRD2 expression based on
Tang H; Cheng Y; Lou X; Yao H; Xie J; Gu W; Huang X; Liu Y; Lin S; Dai Y; Xue L; Lin X; Wu ZB
Endocrine; 2023 May; 80(2):419-424. PubMed ID: 36689171
[TBL] [Abstract][Full Text] [Related]
34. PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes.
Cristina C; Díaz-Torga GS; Goya RG; Kakar SS; Perez-Millán MI; Passos VQ; Giannella-Neto D; Bronstein MD; Becu-Villalobos D
Mol Cancer; 2007 Jan; 6():4. PubMed ID: 17222350
[TBL] [Abstract][Full Text] [Related]
35. PRL-R Variants Are Not Only Associated With Prolactinomas But Also With Dopamine Agonist Resistance.
de Castro Moreira AR; Trarbach E; Bueno CBF; Monteiro ALS; Grande IPP; Padula M; Maciel GAR; Glezer A
J Clin Endocrinol Metab; 2023 Jun; 108(7):e450-e457. PubMed ID: 36638053
[TBL] [Abstract][Full Text] [Related]
36. Prolactinomas in pregnancy: considerations before conception and during pregnancy.
Glezer A; Bronstein MD
Pituitary; 2020 Feb; 23(1):65-69. PubMed ID: 31792668
[TBL] [Abstract][Full Text] [Related]
37. PBK/TOPK Inhibitor Suppresses the Progression of Prolactinomas.
Zhu K; Cheng X; Wang S; Zhang H; Zhang Y; Wang X; Chen Y; Wu J
Front Endocrinol (Lausanne); 2021; 12():706909. PubMed ID: 35126305
[TBL] [Abstract][Full Text] [Related]
38. Frequency of pituitary tumor apoplexy during treatment of prolactinomas with dopamine agonists: a systematic review.
Carija R; Vucina D
CNS Neurol Disord Drug Targets; 2012 Dec; 11(8):1012-4. PubMed ID: 23244423
[TBL] [Abstract][Full Text] [Related]
39. T2-weighted magnetic resonance imaging characterization of prolactinomas and association with their response to dopamine agonists.
Burlacu MC; Maiter D; Duprez T; Delgrange E
Endocrine; 2019 Feb; 63(2):323-331. PubMed ID: 30267354
[TBL] [Abstract][Full Text] [Related]
40. miR-93-5p targets Smad7 to regulate the transforming growth factor-β1/Smad3 pathway and mediate fibrosis in drug-resistant prolactinoma.
Hu B; Mao Z; Du Q; Jiang X; Wang Z; Xiao Z; Zhu D; Wang X; Zhu Y; Wang H
Brain Res Bull; 2019 Jul; 149():21-31. PubMed ID: 30946881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
